|
|
Post by Tony Crispino on Dec 20, 2013 17:03:29 GMT -8
|
|
Jerry
Junior Member
Posts: 44 
|
Post by Jerry on Dec 20, 2013 17:52:28 GMT -8
Abiraterone will prove to be an amazing drug for PC.
|
|
|
|
Post by Tony Crispino on Dec 20, 2013 17:59:35 GMT -8
It already has. I am just thrilled for Todd. A 3200 PSA is still in check 8 years later. Amazing.
Tony
|
|
|
|
Post by Evan Yu on Dec 22, 2013 7:31:01 GMT -8
Tony,
I think this is an important point to bring up, and I'm glad you put it in your forum. Abiraterone, enzalutamide and radium-223 all have pain-associated benefits in patients with metastatic castration-resistant prostate cancer (mCRPC). It is important to keep in mind. In the old days (3-4 years ago), once someone had pain with mCRPC, we felt obligated to reach towards docetaxel chemotherapy (previously shown to decrease pain). But now we have many more options that have less toxicity. Of course the CHAARTED data will be interesting to dissect once all the data comes out, but we have to keep in mind that one positive trial with earlier use of chemotherapy does not extrapolate to every patient and setting. The risk/benefit ratio must always be considered for the individual patient.
Evan
|
|
|
|
Post by Tony Crispino on Dec 22, 2013 15:10:10 GMT -8
Evan, I look forward to GU ASCO and more released data on the CHAARTED trial. Today we know that men with more extensive mets survive longer with early docetaxel but that men with less mets the returns are not as favorable. Of course more time is needed for these men as well. As I understand it, earlier mets survival time frames can be very favorable and the two years median may be too short to measure the effects of earlier chemo in that patient subset. I believe that came out in our last special committee teleconference call.
Haha. Long time ago, "3 to 4 years ago". I take that to indicate the last few years have been terrific in positive changes in the treatment of metastatic prostate cancer. And that's a very good thing.
Thank you for joining our board, kind sir. It was a vital piece of this website to have access to great resources in the research community.
Tony
|
|
